NIH Funding Opportunities and Notices for The Week Ending03-27-2020

Notice of Special Interest (NOSI): Availability of Administrative Supplements to Advance Safe and Effective Therapeutics in Pregnant and Lactating Women and Children
(NOT-HD-20-003)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Human Genome Research Institute
National Institute of General Medical Sciences
National Institute on Minority Health and Health Disparities
National Institute of Neurological Disorders and Stroke

Notice of Special Interest (NOSI): Availability of Administrative Supplements for Providing Research Experiences for Data Scientists
(NOT-HG-20-029)
National Human Genome Research Institute

Notice of Special Interest (NOSI): NHLBI and NIDA Announce Availability of Administrative Supplements for HEAL Awardees to Address Sleep Impairments in OUD Treatment Response and Recovery Outcomes
(NOT-HL-20-746)
National Heart, Lung, and Blood Institute
National Institute on Drug Abuse

Notice of Special Interest: Health Services Research on Minority Health and Health Disparities (R01- Clinical Trial Optional)
(NOT-MD-20-011)
National Institute on Minority Health and Health Disparities
National Cancer Institute
National Institute on Alcohol Abuse and Alcoholism
National Institute on Drug Abuse
National Institute of Dental and Craniofacial Research
Office of Behavioral and Social Sciences Research

Notice of Special Interest (NOSI): Strengthening the HIV Prevention Continuum
(NOT-MH-20-019)
National Institute of Mental Health

Notice of Special Interest (NOSI): Administrative Supplements to NINR Predoctoral Training Grants to Enhancing Training in Genomics
(NOT-NR-20-003)
National Institute of Nursing Research
National Human Genome Research Institute

Notice of Special Interest (NOSI): Research to Improve the Interpretation of Patient-Reported Outcomes at the Individual Patient Level for Use in Clinical Practice
(NOT-OD-20-079)
Office of Behavioral and Social Sciences Research
National Center for Complementary and Integrative Health
National Cancer Institute
National Human Genome Research Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute on Deafness and Other Communication Disorders
National Institute of Mental Health
National Institute on Minority Health and Health Disparities
National Institute of Neurological Disorders and Stroke
National Institute of Nursing Research
Office of Disease Prevention
Office of Research on Women's Health

Notice of Special Interest: Research to Advance the Understanding of Tobacco Product Pharmacokinetic Research
(NOT-OD-20-081)
Office of Disease Prevention
U.S. Food and Drug Administration, Center for Tobacco Products
Food and Drug Administration
National Cancer Institute
National Institute on Alcohol Abuse and Alcoholism
National Institute on Drug Abuse
National Institute of Environmental Health Sciences

Notice of Special Interest: Non-Viral Technologies for in vivo Delivery of Genome Editors (R43/R44 Clinical Trial Not Allowed)
(NOT-OD-20-084)
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Notice of Special Interest: Non-Viral Technologies for in vivo Delivery of Genome Editors (R41/R42 Clinical Trial Not Allowed)
(NOT-OD-20-085)
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need
(NOT-TR-20-011)
National Center for Advancing Translational Sciences

Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)
(NOT-TR-20-012)
National Center for Advancing Translational Sciences

Funding Opportunities

Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)
(PA-20-144)
National Institute of Mental Health
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
(PA-20-145)
National Institute of Mental Health
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
NIDA Small Research Grant Program (R03 Clinical Trial Required)
(PA-20-146)
National Institute on Drug Abuse
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is June 16, 2020.
Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R01- Clinical Trial Not Allowed)
(PAR-20-147)
National Institute on Drug Abuse
Application Receipt Date(s): October 13, 2020, March 15, 2021, October 13, 2021, March 15, 2022, October 13, 2022, March 15, 2023
Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed)
(PAR-20-148)
National Institute on Drug Abuse
Application Receipt Date(s): October 13, 2020, March 15, 2021, October 13, 2021, March 15, 2022, October 13, 2022, March 15, 2023 Standard dates apply. The first standard due date for this FOA is October 5, 2020
NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)
(PAR-20-150)
National Institute on Minority Health and Health Disparities
Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is June 16, 2020.
Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)
(RFA-AI-20-007)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): August 28, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Long Acting Treatments for HIV and HIV-Associated Co-Infections (R61/R33 Clinical Trial Not Allowed)
(RFA-AI-20-024)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional)
(RFA-DA-21-005)
National Institute on Drug Abuse
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
Special Topic Research Education Course: Exploring Auditory and Vestibular Biology (R25 - Clinical Trial Not Allowed)
(RFA-DC-20-001)
National Institute on Deafness and Other Communication Disorders
Application Receipt Date(s): June 26, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
Revolutionizing Innovative, Visionary Environmental Health Research (RIVER) (R35 Clinical Trial Optional)
(RFA-ES-20-009)
National Institute of Environmental Health Sciences
Application Receipt Date(s): June 18, 2020
Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry Centers (U01 Clinical Trial Not Allowed)
(RFA-HG-20-001)
National Human Genome Research Institute
National Cancer Institute
Office of Research on Women's Health
Application Receipt Date(s): June 23, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry Coordinating Center (U01 Clinical Trial Not Allowed)
(RFA-HG-20-002)
National Human Genome Research Institute
Application Receipt Date(s): June 23, 2020 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.